Comparing the effects of cabergoline and hydroxychloroquine to prevent ovarian hyperstimulation syndrome

Phase 3

Conditions: Polycystic ovary syndrome.
Polycystic ovarian syndrome
E28.2

Registration Number: IRCT20240305061171N1

Lead Sponsor: Tehran University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Complete

Sex: Female

Target Recruitment: 40

Inclusion Criteria

Polycystic ovary syndrome according to Rotterdam criteria
Age 18 to 40 years
The number of antral follicles (AFC) above 20
Anti-Müllerian hormone (AMH) more than 3.36 ng/ml
Body mass index (BMI) less than 30 kg/m2

Exclusion Criteria

Suffering from endometriosis
Decreased ovarian reserve
Chromosomal abnormalities
History of sensitivity to drugs that inhibit dopamine or cabergoline
Patients who do not take the desired drugs on a daily basis

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Primary outcome: Ovarian hyperstimulation syndrome (OHSS). Timepoint: After the intervention. Method of measurement: Based on clinical criteria, ultrasound and tests performed.

Secondary Outcome Measures

Name	Time	Method
Secondary outcome: Blood creatinine level. Timepoint: Before starting the intervention, After the intervention. Method of measurement: Based on laboratory results.;Secondary outcome: Blood sodium level. Timepoint: Before starting the intervention, After the intervention. Method of measurement: Based on laboratory results.;Secondary outcome: Blood potassium level. Timepoint: Before starting the intervention, After the intervention. Method of measurement: Based on laboratory results.;Secondary outcome: Blood Hematocrit. Timepoint: Before starting the intervention, After the intervention. Method of measurement: Based on laboratory results.;Secondary outcome: Blood urea level. Timepoint: Before starting the intervention, After the intervention. Method of measurement: Based on laboratory results.